- Home
- TENX
as 11-20-2025 3:32pm EST
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | CHAPEL HILL |
| Market Cap: | 31.9M | IPO Year: | N/A |
| Target Price: | $17.00 | AVG Volume (30 days): | 59.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.63 - $8.24 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tenax Therapeutics Inc. (TENX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | TENX | Director | Nov 18 '25 | Buy | $7.52 | 1,900 | $14,279.83 | 1,993 | |
| Almenoff June Sherie | TENX | Director | Nov 17 '25 | Buy | $7.15 | 93 | $664.95 | 1,993 | |
| MCGAULEY THOMAS | TENX | Interim CFO | Nov 17 '25 | Buy | $7.31 | 8,000 | $58,164.00 | 2,000 |
Latest Tenax Therapeutics Inc. News
TENX Breaking Stock News: Dive into TENX Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
Associated Press Finance
9 days ago
Tenax Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
9 days ago
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
15 days ago
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
GlobeNewswire
18 days ago
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Associated Press Finance
6 months ago
Tenax Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
6 months ago
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
8 months ago
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Compare TENX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TENX Tenax Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.